Drugs / p53MVA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02432963 | Jun 2016 → Dec 2017 overdue | colon carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma +7 | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01191684 | Oct 2011 → Aug 2013 | gastric carcinoma, malignant colon neoplasm, pancreas disorder, rectal carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03113487 | Feb 2018 → Aug 2022 overdue | fallopian tube carcinoma, primary peritoneal carcinoma, refractory malignant neoplasm | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | p53MVA | “modified vaccinia virus ankara vaccine expressing p53 (p53MVA) and pembrolizumab” NCT03113487 ↗2“modified vaccinia Ankara (MVA) vaccine delivering wild-type human p53 (p53MVA)” PMID 24987057 ↗ Jul 2014 “A Phase I Study of a p53MVA Vaccine in Combination with Pembrolizumab” NCT02432963 ↗ |
| Known as | p53MVA Vaccine | “A Phase I Study of a p53MVA Vaccine in Combination with Pembrolizumab” NCT02432963 ↗ |
| Modality | Vaccine | “modified vaccinia virus Ankara vaccine expressing p53” NCT02432963 ↗ |
| Route | Subcutaneous | “Patients receive MVAp53 subcutaneously” NCT01191684 ↗ |